Humana Inc.

(New York Stock Exchange)
Back to all articles
Bullish +65

JPMorgan and Mizuho Raise Humana (HUM) Price Targets as Managed Care Outlook Improves - Insider Monkey

AI-generated analysis

πŸ“ˆ JPMorgan raised its price target for Humana (HUM) to $316 from $214 on June 8, 2026.

πŸ“ˆ Mizuho increased its price target for Humana to $390 from $335 and maintained an Outperform rating.

πŸ›οΈ Analysts cite a shift toward a more stable and predictable policy environment as the primary driver for the upgrades.

πŸ” JPMorgan updated its healthcare services models to reflect the changing regulatory landscape.

πŸ’Ό Mizuho believes reduced policy volatility will allow investors to focus on pricing recovery and earnings power.

πŸ₯ Humana operates through two main segments: Insurance and CenterWell health care services.

πŸ“Š The managed care sector is expected to see a decrease in the scale of policy-related surprises compared to the past three years.

Bullish Signals
  • JPMorgan and Mizuho have both raised their price targets for Humana, indicating institutional confidence in the stock's valuation.
  • The managed care sector is transitioning into a more stable regulatory environment, reducing uncertainty for investors.
  • Analysts expect a return to focus on core fundamentals like pricing recovery and underlying earnings power.
  • Humana is recognized as a dividend stock by billionaire investor Larry Robbins.
Risk Factors
  • JPMorgan maintained a Neutral rating despite the price target increase, suggesting caution remains warranted.
  • The article includes promotional content from Insider Monkey recommending other AI stocks, which may distract from Humana's specific merits.
Full Analysis
On June 8, 2026, major financial institutions JPMorgan and Mizuho raised their price targets for Humana Inc. (NYSE: HUM), signaling an improved outlook for the managed care sector. JPMorgan analyst Lisa Gill increased her target to $316 from $214 while maintaining a Neutral rating, citing updated healthcare service models. Simultaneously, Mizuho raised its recommendation to $390 from $335 and reiterated an Outperform rating. The analysts attribute this positive shift to a stabilizing policy environment, noting that the frequency of regulatory surprises has likely decreased after three years of volatility. This stability allows investors to refocus on company fundamentals, pricing recovery, and underlying earnings power within the managed care industry. Mizuho specifically highlighted that the sector is moving toward a more predictable legislative backdrop. Humana operates through two primary segments: Insurance and CenterWell health care services. While the article notes Humana's inclusion in billionaire Larry Robbins' dividend stock picks, it also contains promotional content from Insider Monkey suggesting alternative AI investments, which serves as a distraction rather than substantive analysis of Humana's specific financial performance or operational details.